Ascentage's Aug. 19 Update: 90% Revenue Growth Meets the Dilution Hangover

Aug. 19 is really a credibility check on commercial follow-through

Ascentage has already shown demand. The question now is whether it can show sustainable execution after a large funding event.

In 2025, the company delivered 90% year-over-year revenue growth and US$82.1 million in product sales. That included olverembatinib sales of US$62.2 million, up 81% year over year and lisaftoclax sales of US$10.1 million in the last five months of 2025. Those are real commercial results, not just pipeline promises.

The complication is funding. Just as the business was gaining traction, Ascentage completed a July 2025 top-up placement that generated US$190.1 million in net proceeds. That extends the cash runway, but it also raises the bar. Investors now need evidence that the capital is helping widen access and deepen adoption, rather than simply delaying the next funding conversation.

That is why the Aug. 19 update matters. It is the cleanest near-term check on whether 2025 sales were the start of a larger revenue base or mostly a strong starting point.

Two commercial assets are driving a different kind of debate

The funding debate matters because Ascentage now has enough cash to try to build a broader commercial business around its lead assets.

Olverembatinib remains the core revenue engine

Olverembatinib already benefited from broader NRDL coverage expansion, which helped improve patient access. That remains the company's main commercial proof point today. The key question is whether that access translated into repeatable, growing sales rather than a one-period spike.

Lisaftoclax adds a second commercial variable

Lisaftoclax is the newer growth lever. China's NMPA approved it earlier this year for adults with previously treated CLL/SLL, and Ascentage commenced commercial sales of lisaftoclax in China following that approval. That does not guarantee a major sales contribution yet, but it does give the company a second product to help diversify revenue rather than relying on olverembatinib alone.

The pipeline still has to support the commercial story

Ascentage also reported nine registrational Phase III clinical trials are in progress worldwide, including programs cleared by the FDA and EMA. That pipeline breadth matters because it could support a larger commercial platform later. But it also raises execution risk: investors need to see follow-through across both commercialization and clinical development, not just early approval or early sales.

What to watch in the Aug. 19 update and follow-up webcast

This is a watchlist event, not an automatic buy. The Aug. 19 release sits alongside management's Aug. 20/21 investor webcast, so the real test is whether Ascentage can show the latest quarter built on prior momentum instead of repeating the same narrative.

The clearest benchmarks are already established: olverembatinib H1 2025 sales grew 93% to US$30.3 million, and lisaftoclax launched in China in late July 2025. If those trends are still moving forward, the market can start to look past dilution concerns.

Signals that would strengthen the case

• Management shows that olverembatinib growth is holding up beyond H1 2025.
• Lisaftoclax moves from launch visibility to measurable commercial adoption in China.
• Access metrics stay tied to NRDL-related expansion and hospital/pharmacy availability.
• Cash-position commentary shows how the US$190.1 million in net proceeds changes near-term funding risk.

Signals that would weaken the case

• Q3 or sequential sales slow without a clear, specific commercial explanation.
• Lisaftoclax remains too small to matter after launch.
• Management talks mostly about future potential while avoiding concrete access, uptake, or cash-position details.
• Pipeline commentary advances the story line more than execution.

The practical takeaway is simple: treat this update as a proof-of-momentum check. If Ascentage can show that access is still turning into sales, the funding debate can fade. If not, investors will likely keep focusing on dilution rather than growth.